Usted buscó: deferoxamine (Maltés - Inglés)

nofs id-doża ta’ deferoxamine
half of deferoxamine dose

2/ 3 terapija b' deferoxamine hija kontraindikata jew inadegwata.
2/ 3 which measures are being taken to ensure the safe use of exjade?

it-tagħrif tal-prodott ta’ deferoxamine għandu jiġi kkonsultat.
the product information of deferoxamine should be consulted.

fi studju minnhom li dam sejjer sentejn, deferiprone tqabbel ma ’ deferoxamine.
in one study of two-year duration deferiprone was compared to deferoxamine.

għalhekk deferiprone fid- doża rakkomandata jista ’ jkun inqas effettiv minn deferoxamine.
therefore deferiprone at the recommended dose could be less effective than deferoxamine.

l- istudju ewlieni tal- effikaċja qabbel exjade ma 'deferoxamine f' 591 pazjent bil- beta talassemija major.
the main study of effectiveness compared exjade with deferoxamine in 591 patients with beta thalassaemia major.

madankollu, l- għadd ta ’ pazjenti fl- istudju ma kienx biżżejjed biex ikun ippruvat li skeda bħal din kienet effettiva daqs deferoxamine meħud waħdu.
however, the number of patients in the study was not sufficient to prove that such a schedule is as effective as deferoxamine taken on its own.

minn studji ta ’ qabel l- użu kliniku u studji kliniċi deher li exjade jista ’ jkun attiv daqs deferoxamine meta jintuża f’ proporzjon ta ’ doża ta ’ 2: 1 (i. e. doża ta ’ exjade li tiġi numerikament nofs dik tad- doża ta ’ deferoxamine).
20 it appeared from preclinical and clinical studies that exjade could be as active as deferoxamine when used in a dose ratio of 2:1 (i. e. a dose of exjade that is numerically half of the deferoxamine dose).